HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inhibition of complement activation decreases airway inflammation and hyperresponsiveness.

Abstract
Studies in murine models have suggested the involvement of the complement anaphylatoxins (C3a and C5a) in the development of allergic asthma. We investigated the effects of inhibiting complement activation after sensitization but before allergen challenge on the development of allergic airway inflammation and airway hyperresponsiveness. To prevent complement activation, we used a recombinant soluble form of the mouse membrane complement inhibitor complement receptor-related gene y (Crry) fused to the IgG1 hinge, CH2 and CH3 domains (Crry-Ig), which has decay-accelerating activity for both the classic and alternative pathways of complement as well as cofactor activity for factor I-mediated cleavage of C3b and C4b. C57BL/6 mice were sensitized (Days 1 and 14) and challenged (Days 24-26) with ovalbumin. Crry-Ig was administered after allergen sensitization either as an intraperitoneal injection or by nebulization before allergen challenge. Crry-Ig significantly prevented the development of airway hyperresponsiveness, decreased airway and lung eosinophilia as well as the numbers of lung lymphocytes, decreased levels of interleukin (IL)-4, IL-5, and IL-13 in bronchoalveolar lavage fluid and decreased serum ovalbumin-specific IgE and IgG1. These results suggest that prevention of complement activation may have a therapeutic role in the treatment of allergic airway inflammation and asthma in sensitized individuals.
AuthorsChristian Taube, Yeong-Ho Rha, Katsuyuki Takeda, Jung-Won Park, Anthony Joetham, Annette Balhorn, Azzeddine Dakhama, Patricia C Giclas, V Michael Holers, Erwin W Gelfand
JournalAmerican journal of respiratory and critical care medicine (Am J Respir Crit Care Med) Vol. 168 Issue 11 Pg. 1333-41 (Dec 01 2003) ISSN: 1073-449X [Print] United States
PMID14500265 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Cr1l protein, mouse
  • Immunoglobulin G
  • Proteins
  • Receptors, Complement
  • Receptors, Complement 3b
Topics
  • Animals
  • Bronchial Provocation Tests
  • Complement Pathway, Alternative (drug effects)
  • Complement Pathway, Classical (drug effects)
  • Disease Models, Animal
  • Female
  • Immunoglobulin G (administration & dosage)
  • Inflammation (drug therapy)
  • Mice
  • Mice, Inbred C57BL
  • Proteins (administration & dosage)
  • Receptors, Complement (administration & dosage)
  • Receptors, Complement 3b
  • Respiratory Hypersensitivity (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: